bosakitug
What stands out
New approach in eczema
- Binds to TSLP, a signal that helps activate and attract immune cells
- Injection every week or 2 weeks in trials
Derived from FDA substance registry · NCT05932654 · UniProt Q969D9 · · This is a summary of public records for informational purposes only. It is not medical advice.
History
Earliest recorded event: Oct 25, 2021. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.
- Oct 15, 2025Phase 2 results postedPOC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis ClinicalTrials.gov NCT05932654
- Sep 18, 2024Phase 2 trial completedPOC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis ClinicalTrials.gov NCT05932654
- Jul 31, 2023Phase 2 trial startedPOC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis ClinicalTrials.gov NCT05932654
- Feb 15, 2023Phase 1 trial completedSafety and Tolerability of BSI-045B in Healthy Adult Subjects and Patients With Atopic Dermatitis ClinicalTrials.gov NCT05114889
- Oct 25, 2021Phase 1 trial startedSafety and Tolerability of BSI-045B in Healthy Adult Subjects and Patients With Atopic Dermatitis ClinicalTrials.gov NCT05114889